Research Triangle Park, N.J.-based biotechnology company Liquidia Technologies has announced plans to form an ophthalmology-focused company in response to recent success with products in the therapeutics area.
Liquidia intends to release more information on the new company in the second quarter of 2013. The company's premier product will be designed to treat glaucoma and is expected to enter clinical trials in 2014.
More Articles on Ophthalmology:
La Peer Health Systems Recruits Dr. Aaron Savar
InSite Vision to Present at ARVO 2013
Study Finds 65% of Liver Transplant Patients Develop AMD
Liquidia intends to release more information on the new company in the second quarter of 2013. The company's premier product will be designed to treat glaucoma and is expected to enter clinical trials in 2014.
More Articles on Ophthalmology:
La Peer Health Systems Recruits Dr. Aaron Savar
InSite Vision to Present at ARVO 2013
Study Finds 65% of Liver Transplant Patients Develop AMD